Currently out of the existing stock ratings of Elemer Piros, 193 are a BUY (88.94%), 12 are a HOLD (5.53%), 12 are a SELL (5.53%).

Elemer Piros

Work Performance Price Targets & Ratings Chart

Analyst Elemer Piros, currently employed at LUCID CAPITAL, carries an average stock price target met ratio of 53.03% that have a potential upside of 73.5% achieved within 317 days. Previously, Elemer Piros worked at ROTH MKM, CANTOR FITZGERALD, BENCHMARK.

Elemer Piros’s has documented 422 price targets and ratings displayed on 51 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on INMB, INmune Bio at 11-Mar-2026.

Wall Street Analyst Elemer Piros

Analyst best performing recommendations are on FBRX (FORTE BIOSCIENCES).
The best stock recommendation documented was for FBRX (FORTE BIOSCIENCES) at 9/12/2019. The price target of $375 was fulfilled within 1 day with a profit of $26.25 (7.53%) receiving and performance score of 75.27.

Average potential price target upside

of $1181 (98.75%) on CNAT (CONATUS PHARMACEUTICALS).
of $553 (95.09%) on PTI (PROTEOSTASIS THERAPEUTICS).
of $551.98 (31.82%) on BLUE (BLUEBIRD BIO).

ABEO Abeona Therapeutics AERI Aerie Pharmaceuticals APLS Apellis Pharmaceuticals ARWR Arrowhead Pharmaceuticals BLUE Bluebird bio CMPS Compass Pathways Plc CRBP Corbus Pharmaceuticals DMAC DiaMedica Therapeutics DVAX Dynavax Technologies GKOS Glaukos Corp GWPH GW Pharmaceuticals plc HEPA Hepion Pharmaceuticals OCUL Ocular Therapeutix OMER Omeros ONCE Spark Therapeutics UBX Unity Biotechnology ZYNE Zynerba Pharmaceuticals GBT Global Blood Therapeutics ICPT Intercept Pharmaceuticals ALDX Aldeyra The ARCT Arcturus Therapeutics Holdings ATAI ATAI Life Sciences BV PTE Polarityte CLNN Clene MNMD Mind Medicine AUPH Aurinia Pharmaceuticals BLCM Bellicum Pharmaceuticals BRTX BioRestorative Therapies CYBN Cybin DMTTF Small Pharma FOLD Amicus Therapeutics GHRS GH Research PLC GLMD Galmed Pharmaceuticals Ltd MNPR Monopar Therapeutics QURE Uniqure NV UNCY Unicycive Therapeutics KTTA Pasithea Therapeutics Corp COYA Coya Therapeutics, Common Stock BTAI BioXcel Therapeutics DRRX Durect FBRX Forte Biosciences LUMO Lumos Pharma MESO Mesoblast Ltd PTI Proteostasis Therapeutics SBBP Strongbridge Biopharma plc SAVA Cassava Sciences AER AerCap Holdings NV CNAT Conatus Pharmaceuticals GBTG Global Business Travel Group INMB INmune Bio KRYS Krystal Biotech

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)